Kidney-sparing combo for high-risk ureter cancer
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of an oral targeted drug (DV) and an immunotherapy (Toripalimab) to preserve kidney function in people with high-risk upper tract urothelial cancer (UTUC) who cannot have their kidney and ureter removed. It is for patients with only one kidney, reduced kidney function, or cancer in both ureters.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have high-risk urothelial cancer in the upper urinary tract (ureter or kidney pelvis), and you either have only one kidney, reduced kidney function, or cancer in both ureters
- You have refused or are not eligible for surgery to remove the kidney and ureter (RNU)
- Your cancer is considered high-risk (for example, it causes swelling in the kidney, is at least 2 cm, has certain worrisome features on biopsy or CT scan, or has more than one tumor spot)
- Your overall health allows daily activities with minimal effort (ECOG 0-1)
- Your blood counts and liver/kidney function are within acceptable limits
- You have not taken certain other cancer drugs (PD-1/PD-L1 inhibitors or HER-2 inhibitors) before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining DV with tislelizumab can help protect kidney function in people with high-risk cancer in the upper urinary tract (the renal pelvis or ureter). It may help preserve the kidneys while treating the cancer more effectively.
This trial tests a targeted therapy (disitamab vedotin, also called RC48) given directly into the bladder after surgery for HER2-positive upper tract urothelial cancer. The goal is to see if it helps prevent the cancer from coming back.
This trial tests a combination of an antibody-drug conjugate (Disitamab Vedotin) plus radiation therapy after surgery to prevent upper tract urothelial cancer from coming back. It is for patients with HER2-positive tumors and high-risk features who cannot receive cisplatin chemo.
This trial tests a combination of two drugs (disitamab vedotin and tislelizumab) to treat HER2-positive high-risk upper tract urothelial cancer, aiming to save the kidney instead of removing it. The drugs target cancer cells and boost the immune system to fight the cancer.
This study looks at how well patients do when they have kidney-sparing treatment (instead of complete kidney removal) for upper tract urothelial carcinoma. It helps doctors understand which patients can safely avoid losing their kidney.
This study tests whether combining two drugs—toripalimab (an immunotherapy that boosts your immune system) and 9MW2821 (a targeted drug that delivers treatment directly to cancer cells)—before surgery helps shrink tumors and improves outcomes for people with upper tract urothelial cancer. The goal is to see if this combination is safe and effective before the kidney and ureter are removed.
Hear when a new Renal Insufficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.